Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rLP2086 meningococcal group B vaccine trial in healthy infants
2008-001457-18Phase 2Terminated
- Sponsor
- Wyeth
- Start
- Sep 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (3 arms), sponsored by Wyeth. Primary endpoints: Immunogenicity after infant series, Immunogenicity after toddler dose and 1 more. Started Sep 2008; status: terminated.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2008-001457-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001457-18.